Zavasca milustat Download Zavesca Prescribing Information4 Download ZAVESCA Physician Statement Form Download ZAVESCA Patient Enrollment Form

For the Treatment of Type 1 Gaucher Disease.

We remain dedicated to assisting the type 1 Gaucher disease community, committing to:

  • Provide a reliable supply of quality drug to all patients who take ZAVESCA.
  • Maintain sufficient inventory for patients who are prescribed ZAVESCA.
  • Sustain production capacity to provide ZAVESCA for all appropriate type 1 Gaucher disease patients in the United States.
  • Through our specialty pharmacy provider, CuraScript Inc., offer dedicated support services to patients taking ZAVESCA including help with insurance benefits and financial assistance, nursing support to answer questions about treatment, counseling for diet management, and assistance with other patient concerns.
  • Provide ZAVESCA at no cost to eligible type 1 Gaucher patients with financial hardship, or cover all costs related to co-pay or co-insurance for eligible patients with private insurance, except where prohibited by law.

Zavesca® is indicated for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access).

Important Safety Information for Zavesca:

In clinical studies, the most common adverse events due to Zavesca included weight loss, diarrhea, and trembling in the hand (tremor). Other common adverse reactions were excess gas (flatulence), abdominal pain, and headache. The most common serious adverse reaction was tingling or numbness in the hands or feet with or without pain (peripheral neuropathy). Patients should undergo neurological examination at the start of treatment and every 6 months thereafter; Zavesca should be reassessed in patients who develop symptoms of peripheral neuropathy. Zavesca may cause fetal harm if administered to a pregnant woman. Men should maintain reliable contraceptive methods and not plan to father a child while taking Zavesca and for 3 months after discontinuing treatment.

Please see full Prescribing Information.